Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization

Author:

Mathieu Clélia123ORCID,Ghosh Shayamita123,Draussin Julien123,Gasser Adeline123,Jacquot Guillaume123,Banerjee Mainak123ORCID,Gupta Tanushree4,Schmutz Marc5,Mirjolet Céline67,Tillement Olivier8,Lux François89,Klymchenko Andrey S.4ORCID,Donzeau Mariel10,Pivot Xavier123,Harlepp Sébastien123ORCID,Detappe Alexandre123ORCID

Affiliation:

1. Institut de Cancérologie Strasbourg Europe Strasbourg 67000 France

2. Strasbourg Drug Discovery and Development Institute (IMS) Strasbourg 67000 France

3. Equipe labellisée ligue contre le cancer 26 Rue d'Ulm Paris 75005 France

4. Laboratoire de Bioimagerie et Pathologies Université de Strasbourg UMR 7021 CNRS Illkirch 67401 France

5. Université de Strasbourg CNRS Institut Charles Sadron UPR 22 Strasbourg 67034 France

6. Radiation Oncology Department Preclinical Radiation Therapy and Radiobiology Unit Centre Georges‐François Leclerc Unicancer Dijon 21000 France

7. TIReCS team INSERM UMR 1231 Dijon 21000 France

8. Institut Lumière‐Matière UMR 5306 Université Claude Bernard Lyon1‐CNRS Villeurbanne Cedex France

9. Institut Universitaire de France (IUF) Paris 75231 France

10. Institut de génétique et de biologie moléculaire et cellulaire Illkirch 67404 France

Abstract

AbstractNanoparticle (NP) surface functionalization with proteins, including monoclonal antibodies (mAbs), mAb fragments, and various peptides, has emerged as a promising strategy to enhance tumor targeting specificity and immune cell interaction. However, these methods often rely on complex chemistry and suffer from batch‐dependent outcomes, primarily due to limited control over the protein orientation and quantity on NP surfaces. To address these challenges, a novel approach based on the supramolecular assembly of two peptides is presented to create a heterotetramer displaying VHHs on NP surfaces. This approach effectively targets both tumor‐associated antigens (TAAs) and immune cell‐associated antigens. In vitro experiments showcase its versatility, as various NP types are biofunctionalized, including liposomes, PLGA NPs, and ultrasmall silica‐based NPs, and the VHHs targeting of known TAAs (HER2 for breast cancer, CD38 for multiple myeloma), and an immune cell antigen (NKG2D for natural killer (NK) cells) is evaluated. In in vivo studies using a HER2+ breast cancer mouse model, the approach demonstrates enhanced tumor uptake, retention, and penetration compared to the behavior of nontargeted analogs, affirming its potential for diverse applications.

Funder

Agence Nationale de la Recherche

H2020 European Research Council

Ligue Contre le Cancer

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3